摘要
目的观察来氟米特(LEF)联合甲氨蝶呤(MTX)治疗中老年类风湿关节炎(RA)的疗效及安全性。方法选取我院2022年8月-2024年8月内科收治的80例中老年RA病例,根据随机数表法分为对照组和观察组,每组各40例。对照组单纯应用MTX治疗,观察组在对照组基础上联合应用LEF。治疗12周后对两组临床疗效进行评价,观察两组治疗前后关节情况,统计两组用药不良反应发生情况。结果用药12周后,观察组病情缓解率62.50%、对照组为47.50%,观察组明显高于对照组,P<0.05。治疗前,两组患者晨僵时间、关节压痛数、关节肿胀数、握力情况组间对比,P>0.05;治疗12周后再次评估,两组患者关节情况均有所改善,且观察组明显好于对照组,P<0.05。观察组和对照组患者用药不良反应发生率分别为5.00%、7.50%,两组对比,P>0.05。结论针对中老年类风湿关节炎,应用来氟米特联合甲氨蝶呤治疗,可有效改善关节功能,疗效好,且不良反应少,值得推广。
Objective To observe the efficacy and safety of leflunomide(LEF)combined with methotrexate(MTX)in the treatment of middle-aged and elderly patients with rheumatoid arthritis(RA).Methods 80 middle-aged and elderly patients with RA admitted to our hospital from August 2022 to August 2024 were selected and divided into control group and observation group according to the random number table method,with 40 cases in each group.The control group was treated with MTX alone,while the observation group was treated with lef on the basis of the control group.After 12 weeks of treatment,the clinical efficacy of the two groups was evaluated,the joint conditions of the two groups before and after treatment were observed,and the occurrence of adverse drug reactions in the two groups was counted.Results After 12 weeks of treatment,the remission rate of the observation group was 62.50%and that of the control group was 47.50%,which was significantly higher than that of the control group,P<0.05.Before the intervention,the time of morning stiffness,the number of joint tenderness,the number of joint swelling,and the grip strength of the two groups were compared,P>0.05;after 12 weeks of treatment,the joint conditions of the two groups were improved,and the observation group was significantly better than the control group,P<0.05.The incidence of adverse drug reactions in the observation group and the control group were 5.00%and 7.50%,respectively,P>0.05.Conclusion For middle-aged and elderly patients with rheumatoid arthritis,leflunomide combined with methotrexate can effectively improve joint function,with good curative effect and less adverse reactions,which is worthy of promotion.
作者
赵丽薇
Zhao Liwei(Penglai Traditional Chinese Medicine Hospital,Yantai,Shandong 265600,China)
出处
《首都食品与医药》
2025年第19期78-80,共3页
Capital Food Medicine
